Search

Your search keyword '"Tabouret, E."' showing total 233 results
Start Over Author "Tabouret, E."
233 results on '"Tabouret, E."'

7. High-grade glioma in elderly patients: can the oncogeriatrician help?

Author

Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, and Rousseau F

Subjects
brain tumor, older cancer patient, chemotherapy toxicity, oncogeriatric charter, Geriatrics, RC952-954.6
Abstract

Emeline Tabouret,1 Louis Tassy,2 Olivier Chinot,1 ElodieCrétel,3 Frederique Retornaz,4 Frederique Rousseau5 1Department of Neuro-oncology, Timone Hospital, Marseille, France; 2Department of Medical Oncology, Centre Léon Bérard, Lyon, France; 3Transveral Oncogeriatric Unit, University Hospital Timone, Marseille, France; 4Departmental Gerontologic Center, Marseille, France; 5Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France Abstract: Gliomas are the most frequent primary brain tumors in adults. As the population ages in Western countries, the number of people being diagnosed with glioblastoma is expected to increase. Clinical management of elderly patients with primary brain tumors is difficult, owing to multiple comorbidities, polypharmacy, decreased tolerance to chemotherapy, and an increased risk of radiation-induced neurotoxicity. A few specific randomized studies have shown a benefit for radiotherapy in elderly patients with good performance status. For patients with poor performance status, chemotherapy (temozolomide) has been shown to be associated with prolonged duration of response. Patients with methylated O6-alkylguanine deoxyribonucleic acid alkyltransferase promoter seem to have better outcomes. Oncogeriatrics proposes the geriatric evaluation of elderly patients to improve therapeutic choices and optimize the management of treatment toxicities and comorbidities. Keywords: brain tumor, older cancer patient, chemotherapy toxicity, oncogeriatric charter

Published
2013

10. P04.08 Biopsy-only glioblastoma (BO-GBM) as a heterogeneous group of patients

Author

Harlay, V, primary, Loundou, A, additional, Boucard, C, additional, Petrirena, G, additional, Barrie, M, additional, Campello, C, additional, Autran, D, additional, Padovani, L, additional, Figarella, D, additional, Boissonneau, S, additional, Dufour, H, additional, Baumstarck, K, additional, Tabouret, E, additional, and Chinot, O, additional

Published
2021
Full Text
View/download PDF

12. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)

Author

Ducray, F, primary, Sanson, M, additional, Chinot, O, additional, Fontanilles, M, additional, Rivoirard, R, additional, Thomas-Maisonneuve, L, additional, Cartalat, S, additional, Tabouret, E, additional, Bonneville-Levard, A, additional, Darlix, A, additional, Ameli, R, additional, Meyronet, D, additional, Gueyffier, F, additional, Remontet, L, additional, Maucort-Boulch, D, additional, Dehais, C, additional, and Honnorat, J, additional

Published
2021
Full Text
View/download PDF

13. P11.04 Autonomy duration as analyzed by KPS≥70 cumulative time in patients with biopsy-only glioblastoma (BO-GBM). A sub-analysis of the Timone cohort

Author

Harlay, V, primary, Loundou, A, additional, Boucard, C, additional, Petrirena, G, additional, Barrie, M, additional, Campello, C, additional, Autran, D, additional, Padovani, L, additional, Figarella, D, additional, Boissonneau, S, additional, Dufour, H, additional, Baumstarck, K, additional, Tabouret, E, additional, and Chinot, O, additional

Published
2021
Full Text
View/download PDF

15. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study

Author

Montégut, C., primary, Guillamo, J.-S., additional, Ducray, F., additional, Dehais, C., additional, Chinot, O., additional, Cohen-Jonathan Moyal, E.L., additional, Le Rhun, E., additional, Loiseau, H., additional, Appay, R., additional, Figarella-Branger, D., additional, Delattre, J.-Y., additional, and Tabouret, E., additional

Published
2019
Full Text
View/download PDF

29. Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients

Author

Anne Hulin, Olivier Chinot, Maryline Barrie, Tabouret E, Thiebault L, Benoit Rousseau, and Céline Bequet

Subjects
medicine.medical_specialty, Chemotherapy, Predictive marker, genetic structures, Bevacizumab, business.industry, medicine.medical_treatment, Recurrent glioblastoma, Omics, medicine.disease, Gastroenterology, eye diseases, Surgery, Internal medicine, Glioma, medicine, Trough Concentration, sense organs, business, Body mass index, medicine.drug
Abstract

Purpose: Predictive marker of bevacizumab activity is an unmet medical need. Our objective was to evaluate the trough concentration of bevacizumab in patients with recurrent glioblastoma and to analyze its potential association with patient characteristics and outcome. Methods: We retrospectively included patients with recurrent glioblastoma treated with bevacizumab and chemotherapy with available plasma collected before the second bevacizumab administration (residual time). Trough bevacizumab concentrations and antibodies against bevacizumab were quantified by enzyme linked immunosorbent assay (ELISA). Results: We included 21 patients with a median age of 63.4 years at bevacizumab initiation. Occurrence of antibody against bevacizumab was not observed. Median pre-cycle 2 trough concentration of bevacizumab was 87.1 μg/mL (range, 21.7 μg/mL -151.8 μg/mL). Trough concentration of bevacizumab was not correlated to patient age (p=.529), gender (p=.622), weight (p=.403), size (p=.871), Body Mass Index (p=.439), Karnofsky Performans Status (p=.988) and steroid intake (p=0.403). No correlation was found between trough bevacizumab concentration and response rate (p=.856). The highest tertile of trough bevacizumab concentration tended to be associated with poor progression-free survival (p=0.152), while no correlation was observed for overall survival. Conclusion: Evaluation of the trough concentration of bevacizumab during treatment for patients with glioblastoma is feasible and highly variable. Its prognostic value should be explored in prospective trial.

Published
2015
Full Text
View/download PDF

30. Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis

Author

Lee, CH, Chung, CK, Jahng, TA, Kim, KJ, Kim, CH, Hyun, SJ, Kim, HJ, Jeon, SR, Chang, UK, Lee, SH, Moon, SH, Majeed, H, Zhang, D, Gravis, G, Wibmer, C, Kumar, N, Moon, KY, Park, JH, Tabouret, E, Fuentes, S, Lee, CH, Chung, CK, Jahng, TA, Kim, KJ, Kim, CH, Hyun, SJ, Kim, HJ, Jeon, SR, Chang, UK, Lee, SH, Moon, SH, Majeed, H, Zhang, D, Gravis, G, Wibmer, C, Kumar, N, Moon, KY, Park, JH, Tabouret, E, and Fuentes, S

Published
2016

31. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial

Author

Tabouret, E., primary, Houillier, C., additional, Martin-Duverneuil, N., additional, Blonski, M., additional, Soussain, C, additional, Ghesquières, H., additional, Houot, R., additional, Larrieu, D., additional, Soubeyran, P., additional, Gressin, R., additional, Gyan, E., additional, Chinot, O., additional, Taillandier, L., additional, Choquet, S., additional, Alentorn, A., additional, Leclercq, D., additional, Omuro, A., additional, Tanguy, M.L., additional, and Hoang-Xuan, K., additional

Published
2016
Full Text
View/download PDF

34. Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study

Author

Valyraki, N., Ahle, G., Tabouret, E., Houot, R., Jardin, F., Ghesquières, H., Schmitt, A., Paillassa, J., Choquet, S., Soussain, C., Ursu, R., Nichelli, L., Legarff-Tavernier, M., Mathon, B., Rozenblum, L., Mokhtari, K., Hoang-Xuan, K., and Houillier, C.

Abstract

Primary central nervous system lymphoma (PCNSL) mainly affects the brain (>90% cases); there are very little data pertaining to PCNSL involving the spinal cord.

Published
2024
Full Text
View/download PDF

38. 2904 Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Independent review of a prospective ANOCEF randomized phase II trial

Author

Tabouret, E., primary, Houillier, C., additional, Martin-Duverneuil, N., additional, Blonski, M., additional, Soussain, C., additional, Ghesquieres, H., additional, Houot, R., additional, Delwail, V., additional, Soubeyran, P., additional, Gressin, R., additional, Gyan, E., additional, Lemercier, S., additional, Chinot, O., additional, Taillandier, L., additional, Tanguy, M.L., additional, Antonio, O., additional, and Hoang-Xuan, K., additional

Published
2015
Full Text
View/download PDF

43. AI-29 * ANGIOGENIC SWITCH FROM VEGFR2/HIF1 IN NEWLY DIAGNOSED GLIOBLASTOMA (GB) TO CXCR4-SDF1 PATHWAY IN RECURRENT PAIRED TUMOR AFTER RADIOTHERAPY (RT)-TEMOZOLOMIDE (TMZ)

Author

Tabouret, E., primary, Tchoghandjian, A., additional, Denicolai, E., additional, Delfino, C., additional, Metellus, P., additional, Padovani, L., additional, Nanni, I., additional, Barrie, M., additional, Boucard, C., additional, Ouafik, L., additional, Figarella-Branger, D., additional, and Chinot, O., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results